StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$44.89−1.96 (-4.18%)

Close on Nov 18, 2026Market cap $3.29BP/E –Yield –

Enliven Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Enliven Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$124.41M. For fiscal 2025 it was -$119.66M. The highest annual figure on record is -$24.12M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$119.66M–
FY2024Dec 31, 2024-$104.55M–
FY2023Dec 31, 2023-$83.53M–
FY2022Dec 31, 2022-$38.79M–
FY2021Dec 31, 2021-$51.44M–
FY2020Dec 31, 2020-$41.70M–
FY2019Dec 31, 2019-$24.12M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$37.21M–
Q1 FY2026Mar 31, 2026-$27.82M–
Q4 FY2025Dec 31, 2025-$34.29M–
Q3 FY2025Sep 30, 2025-$25.10M–
Q2 FY2025Jun 30, 2025-$28.58M–
Q1 FY2025Mar 31, 2025-$31.69M–
Q4 FY2024Dec 31, 2024-$26.90M–
Q3 FY2024Sep 30, 2024-$27.07M–
Q2 FY2024Jun 30, 2024-$24.60M–
Q1 FY2024Mar 31, 2024-$25.99M–
Q4 FY2023Dec 31, 2023-$22.73M–
Q3 FY2023Sep 30, 2023-$24.25M–
Q2 FY2023Jun 30, 2023-$20.13M–
Q1 FY2023Mar 31, 2023-$16.42M–
Q4 FY2022Dec 31, 2022-$10.16M–
Q3 FY2022Sep 30, 2022-$10.93M–
Q2 FY2022Jun 30, 2022-$9.02M–
Q1 FY2022Mar 31, 2022-$8.68M–
Q4 FY2021Dec 31, 2021-$14.33M–
Q3 FY2021Sep 30, 2021-$13.66M–
Q2 FY2021Jun 30, 2021-$13.17M–
Q1 FY2021Mar 31, 2021-$10.28M–
Q4 FY2020Dec 31, 2020-$11.55M–
Q3 FY2020Sep 30, 2020-$12.49M–
Q2 FY2020Jun 30, 2020-$10.30M–
Q1 FY2020Mar 31, 2020-$7.35M–
Q4 FY2019Dec 31, 2019-$7.48M–
Q3 FY2019Sep 30, 2019-$6.88M–
Q2 FY2019Jun 30, 2019-$5.56M–
Q1 FY2019Mar 31, 2019-$4.19M–

More Enliven Therapeutics figures

See a number that looks wrong?